Chlorthalidone Tablet
Description
MGLROOT-12.5
Chlorthalidone 12.5 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Chlorthalidone IP — 12.5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
MGLROOT-12.5 contains Chlorthalidone 12.5 mg, a long-acting thiazide-like diuretic formulated for the effective management of hypertension, edema associated with cardiovascular and renal disorders, and long-term cardiovascular risk reduction. Chlorthalidone provides sustained blood pressure control by promoting sodium and water excretion, reducing plasma volume, decreasing peripheral vascular resistance, and offering prolonged antihypertensive activity.
Chlorthalidone is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, isolated systolic hypertension, heart failure, chronic kidney disease, and edema-related conditions. It helps reduce systolic and diastolic blood pressure, improve volume control, decrease arterial stiffness, and lower the risk of cardiovascular complications such as stroke, heart failure, and myocardial infarction.
MGLROOT-12.5 is particularly beneficial for patients requiring long-duration blood pressure control, elderly hypertensive patients, patients with salt-sensitive hypertension, edema, chronic kidney disease, and long-term diuretic therapy.
Technical Knowledge of Chlorthalidone
Chlorthalidone acts primarily on the distal convoluted tubule of the nephron by inhibiting sodium and chloride reabsorption. This increases urinary excretion of sodium, chloride, and water, resulting in reduced plasma volume and decreased cardiac output during the initial phase of therapy.
Long-term antihypertensive activity is primarily attributed to reduction in peripheral vascular resistance, improvement in vascular compliance, and sustained arterial blood pressure reduction. Chlorthalidone has a longer elimination half-life than hydrochlorothiazide, providing prolonged therapeutic activity and more consistent 24-hour blood pressure control.
Mechanism of Action
Chlorthalidone inhibits sodium and chloride reabsorption in the distal convoluted tubule, increases urinary sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, improves vascular compliance, and lowers blood pressure.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Provides prolonged 24-hour antihypertensive action
Long-acting thiazide-like diuretic therapy
Reduces plasma volume and peripheral vascular resistance
Supports cardiovascular protection
Effective in isolated systolic hypertension
Suitable for long-term hypertension management under medical supervision
Clinical Applications
MGLROOT-12.5 is commonly prescribed for essential hypertension, isolated systolic hypertension, edema associated with heart failure, chronic kidney disease, fluid retention disorders, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Chlorthalidone
Chlorthalidone is a long-acting thiazide-like diuretic with extensive clinical evidence supporting its effectiveness in hypertension management and cardiovascular risk reduction. Comparative studies have demonstrated superior duration of antihypertensive action and stronger evidence for cardiovascular event reduction compared with several other diuretics. It is widely recommended in hypertension treatment guidelines because of its proven efficacy in reducing stroke, heart failure, and cardiovascular morbidity.
Key Facts
Long-acting thiazide-like diuretic
Chlorthalidone 12.5 mg for sustained blood pressure control
Provides prolonged 24-hour antihypertensive activity
Effective in isolated systolic hypertension
Supports long-term cardiovascular protection
Evidence-based diuretic therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
MGLROOT-12.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, heart failure, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose MGLROOT-12.5 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Chlorthalidone 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
MGLROOT-12.5 from DIABGLYM combines sustained blood pressure control, prolonged diuretic activity, comprehensive cardiovascular protection, evidence-based antihypertensive therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Chlorthalidone formulation.
